B Cell Precursor Acute Lymphoblastic Leukemia clinical trials

Explore recruiting b cell precursor acute lymphoblastic leukemia clinical trials.

Recruiting b cell precursor acute lymphoblastic leukemia studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

B Cell Precursor Acute Lymphoblastic Leukemia trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Measurable residual disease driven strategy for one or two infusions of nonviral, transposon-manipulated CARCIK CD19 cells. A Phase II study in pediatric and adult patients with relapsed/refractory B cell precursor ALL (BCP-ALL).

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

An open label, phase I/II study of Venetoclax in addition to Blinatumomab immunotherapy in adult patients with relapsed/refractory B cell precursor acute lymphoblastic leukemia (BCP-ALL)

Germany

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Phase 3 Randomized, Controlled Study of Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia With Safety Run-in (Golden Gate Study)

Belgium, Denmark, Netherlands, Sweden, Spain, Romania +11 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 1b/2 Study to Investigate the Safety, Efficacy and Pharmacokinetics of Administration of Subcutaneous (SC) Blinatumomab in Pediatric Participants with Relapsed/Refractory (R/R) and Minimal Residual Disease Positive (MRD+) B Cell Precursor Acute Lymphoblastic Leukemia (B-ALL)

France, Netherlands, Italy

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Phase I clinical trial on the use of fresh, allogeneic, second-generation CD19-CAR T cells for treatment of children and young adult with relapsed/refractory B-cell Acute Lymphoblastic Leukemia

Italy

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A Phase 1/2 Open-label Study to Investigate the Safety, Efficacy, and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Adults and Adolescents with Relapsed or Refractory B cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL) and Minimal Residual Disease Positive (MRD+) B-ALL

Italy, Germany, Spain, Netherlands, France, Romania +1 more

Phase I and Phase II (Integrated)- Other EU CTIS Study details

B Cell Precursor Acute Lymphoblastic Leukemia trials by city

B Cell Precursor Acute Lymphoblastic Leukemia in Toronto B Cell Precursor Acute Lymphoblastic Leukemia in Vancouver B Cell Precursor Acute Lymphoblastic Leukemia in Montreal B Cell Precursor Acute Lymphoblastic Leukemia in Calgary B Cell Precursor Acute Lymphoblastic Leukemia in Edmonton B Cell Precursor Acute Lymphoblastic Leukemia in Ottawa B Cell Precursor Acute Lymphoblastic Leukemia in Winnipeg B Cell Precursor Acute Lymphoblastic Leukemia in Quebec City B Cell Precursor Acute Lymphoblastic Leukemia in Hamilton B Cell Precursor Acute Lymphoblastic Leukemia in Kitchener B Cell Precursor Acute Lymphoblastic Leukemia in London B Cell Precursor Acute Lymphoblastic Leukemia in Halifax B Cell Precursor Acute Lymphoblastic Leukemia in New York B Cell Precursor Acute Lymphoblastic Leukemia in Los Angeles B Cell Precursor Acute Lymphoblastic Leukemia in Chicago B Cell Precursor Acute Lymphoblastic Leukemia in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease